Report on SRIA consultation for EP PerMed

Publication of the report on the open consultation for the Strategic Research and Innovation Agenda (SRIA) in support for the European Partnership for Personalised Medicine, EP PerMed.

The EP PerMed Drafting Group, representing the European Members States group, has launched an open consultation to validate and receive input for the Strategic Research and Innovation Agenda in support for the European Partnership for Personalised Medicine, EP PerMed. 129 persons from 21 countries filled the questionnaire and thereby took the opportunity to share their view on future activities for accelerating the development and implementation of Personalised Medicine approaches. The open consultation resulted in an overall validation of the identified ToAs. Beyond that, seven additional ToAs were suggested by the participants of the open consultation and in total 13 ToAs received suggestions for adaptions in wording or content.

The detailed report on the open consultation is available here.

EP PerMed: Open Consultation for the SRIA

Publication of the Strategic Research and Innovation Agenda for Personalised Medicine

ERA PerMed is happy to announce the publication of the Strategic Research and Innovation Agenda (SRIA) for Personalised Medicine (PM). This SRIA will support a wide range of stakeholders and experts to further develop programs, activities, and research towards PM and care, as well as prevention. In line with this mission, its main intention is to support the planned new European Partnership for Personalised Medicine (EP PerMed).

The SRIA aims to ensure that the long-term vision of EP PerMed is translated into tailored roadmaps with funding and supporting activities, objectives and measurable outcomes. Therewith, the SRIA complements the EP PerMed proposal that has recently been submitted to the European Commission (EC).

The SRIA was developed by a dedicated drafting group, composed of Member States’ representatives and in close collaboration with the EC. The drafting group was established in 2021 in order to support the first phase of the EP PerMed preparations, i.e. the development of a draft proposal for EP PerMed, that was published by the EC in February 2022, and the SRIA for PM.

The structure and content of the SRIA is based on the drafting group members’ knowledge, existing strategic documents, and further available information. Even more importantly, it presents the outcome of several activities and events of which some were organised with the support of the EC, the International Consortium for Personalised Medicine (ICPerMed), and connected consortia like the European Research Area Network for Personalised Medicine (ERA PerMed).

Among these activities were interviews with more than 70 experts and stakeholders to gather general ideas, recommendations, and information related to PM and, particularly, to identify so called “Triplets of Action”, short “ToA”, defining concrete challenges, objectives, and the expected outcome of actions to foster PM research and implementation of innovative PM approaches. These ToAs are the core elements of the SRIA. They are presented along the main areas crucial for an effective development of PM, also called the value continuum: “interdisciplinary research and development efforts”, “successful innovation” and finally, “implementation of PM approaches into healthcare”. Further ToAs were identified for “overarching activities” to support PM development and implementation.

The first set of 47 identified ToAs was validated in an online consultation (November -December 2022), supported by ICPerMed. The drafting group utilised the findings and suggestions to further refine the SRIA. The results have been published as a report on the ICPerMed website and the ERA PerMed website in March 2023.

Together with ICPerMed, an expert workshop was arranged in Pamplona in January 2023. This event was dedicated to topics and areas crucial for the development and implementation of PM approaches based on interdisciplinary research achievements and has been a significant contribution to the SRIA. A report summarising this workshop has recently been published on the ICPerMed website.

In this 1^st version of the SRIA for PM (2023), in total 57 ToAs and other valuable recommendations and conclusions are presented to enable the future development and implementation of PM approaches for the benefit of patients and sustainable healthcare systems. The SRIA for PM is a living document that will be updated according to latest advances and crucial developments of relevance.

For any questions around the SRIA or EP PerMed, please contact eppermed@dlr.de.

EP PerMed SRIA

EP PerMed: Open Consultation for the SRIA

Launch of an open consultation for the Strategic Research and Innovation Agenda (SRIA) in support for the European Partnership for Personalised Medicine, EP PerMed. Opportunity for participation and contribution to future activities and strategies in personalised medicine.

The EP PerMed Drafting Group, representing the European Members States group, is launching an open consultation to validate and receive input for the Strategic Research and Innovation Agenda in support for the European Partnership for Personalised Medicine, EP PerMed. The outcome of the online consultation will be considered for the SRIA finalisation (02/2023) and the EP PerMed proposal (04/2023) as well as for developing activities and calls within the EP PerMed lifetime (Q4/2023-2030).

The open consultation will close on 31 December 2022.

The open consultation can be accessed through this link:

http://enquetes.agencerecherche.fr/index.php/survey/index/sid/976696/lang/en

This questionnaire will take around 30 min to complete.

By taking part in this survey, participants can share their view on future activities and research for accelerating the implementation of personalised medicine approaches. Input from the whole spectrum of stakeholders and experts involved in the personalised medicine areas is encouraged, such as scientists, healthcare professionals, patients, citizens, policy advisors or individuals working in the pharma industry and biotech.

European Partnership for Personalised Medicine (EP PerMed)

The EP PerMed is one of the European research and innovation partnerships under Horizon Europe which will be dedicated to maximising the benefits of personalised medicine (PM) approaches. The European Commission and Member States have made large investments in personalised medicine over the years and this partnership builds on many of these investments. The core of the partnership is to invest in multidisciplinary, transnational research (basic, clinical, and translational) and innovation activities that will build and disseminate new knowledge, develop new technologies and methods, as well as supporting testing and piloting of the implementation of PM approaches. The partnership will work in close collaboration with other health partnerships and reach out to national, regional, and international initiatives and frameworks to ensure synergies and investments of scale. In addition, the partnership will include supportive activities contributing to policy, regulatory science and strengthening the field of health economics. Early this year, a draft proposal was published. At present the consortium is formed to draft the proposal for submission to the EC in April 2023. The investments from both Member States and the Commission for the 7-10 years duration of the partnership is expected to be over 300 Mio. Euros.

The EP PerMed Strategic Research and Innovation Agenda (SRIA), which is currently in preparation will guide the funding and supporting activities.

Strategic Research and Innovation Agenda (SRIA) to support the EP PerMed

All European Partnerships (EP) develop a SRIA before their launch to ensure that their long-term vision is translated into tailored roadmaps with activities, objectives and measurable outcomes.

The EP PerMed SRIA presents gaps, needs and challenges which should be addressed to maximise the benefits of Personalised Medicine approaches and ensure that there is an equal access to these approaches. The SRIA is divided into four areas of activities, “interdisciplinary research including basic, translational and clinical”, “innovation system” and “implementation” as well as “Overarching activities”. The consortium together with international experts and stakeholders have collected input and analysed reports. The drafting group, with kind support of the European Commission, organised almost 70 interviews with a diverse set of stakeholders. The interviews were translated into Triplets of Action (further explained below), where applicable.

A key element of the SRIA are the so-called Triplets of Action (challenge/objective/outcome) related to personalised medicine. The challenge/objective/outcome sequence allows to specify gaps, needs and actions in a structured and comparable way, following this definition:

Challenge: Description of the status quo, indication what is still lacking, why this is the case and what negative consequences this has.
Objectives: Indicates what exactly should be done to address the challenge in terms of specific actions.
Outcome: Description of how the situation will have improved once the actions described in the objectives have been successfully implemented.

The Triplets of Action will give an overview of needs and gaps and guide the prioritisation of challenges and subsequent actions. So far, over the different areas and chapters of the SRIA a total of 47 Triplets of Action were identified. This list is not exhaustive and open for further input and refinement.

In a pre-final step (November 2022), the Drafting Group performs now an online consultation for the following purposes:

Communication of the SRIA in general and the identified “Triplets of Action” in specific.
To obtain general input, especially related to the “Triplets of Action”
Input regarding the urgency and timing of the “Triplets of Action”
To obtain suggestions for additional “Triplets of Action”

The drafting group thanks the more than 70 experts that participated in the interviews and all participants of this open consultation for their time, their dedication to the topic and their kind input.

The open consultation can be accessed through this link: http://enquetes.agencerecherche.fr/index.php/survey/index/sid/976696/lang/en

This questionnaire will take around 30 min to complete.

In case of technical questions, please contact: monika.frenzel@anr.fr

For general questions regarding the EP PerMed and the SRIA, please contact: EPPerMed@dlr.de

Elementor #6779

Draft Proposal “European Partnership on Personalised Medicine”

As next step towards a European Partnership for Personalised Medicine, a drafting group was established by the Member States in close collaboration with the European Commission.

With support and guidance from the European Commission, they developed a draft proposal for the Partnership that was published by the European Commission in February 2022 in this link.

The vision of the European Partnership for Personalised Medicine is: To improve health outcomes within sustainable healthcare systems through research, and the development and implementation of personalised medicine approaches for the benefit of patients, citizens and society.

This is a further step in the establishment and preparation of the partnership for personalised medicine, to be co-funded by the EC in the European Union’s 9th Framework Programme for Research and Innovation, Horizon Europe.

To realise its vision, the partnership will integrate all the elements needed in a collaborative effort to achieve the full potential of personalised medicine:

Generate research and results through funding activities for example via transnational and cross-sectorial research consortia, networks, pilots and collaborations.
The partnership will be the most significant platform and initiative to connect key stakeholders in the personalised medicine field to share evidence, demonstrate solutions and to drive supportive activities in policy, regulatory science and health economics.

The EP PerMed aims to align and promote national and regional priority setting and funding for research and implementation projects in the area of personalised medicine between the EU Member States (MS), regions and associated countries as well as international partner countries.

JOINT TRANSNATIONAL CALL 2022

“PREVENTION IN PERSONALISED MEDICINE”

THE CALL IS CLOSED

ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 33 funding organisations have agreed to launch the fifth Joint Transnational Call for collaborative innovative research projects in PM. This represents the fourth additional call non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 29 Mio € (approx.).

Opening of online submission tool: 1st December 2021
Submission deadline for pre-proposals: 17 February 2022 (17:00 CEST)
Submission deadline for invited full-proposals: 14 June 2022 (17:00 CEST)

Electronic submission website

Electronic proposal submission is mandatory on PT-Outline. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on “Sign up” and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The ERA PerMed JCS is hosted by the Agence Nationale de la Recherche (ANR), France:

- - Monika Frenzel and Michael Joulie
  - 50 Avenue Daumesnil, 75012 Paris, FRANCE
  - Phone: +33 1 73 54 83 32 / +33 1 80 48 83 57
  - Email: ERAPerMed@agencerecherche.fr
with the support of the National Health Institute Carlos III (ISCIII), Spain.

CALL Documents

The call text and all additional documents can be downloaded below or on the online submission tool:

Call Text (updated on 16.02.2022)
Guidelines for Applicants (updated on 28.04.2022)
Pre-Proposal form
Full-Proposal form (available now)
Annex template for exploratory clinical studies (available now)
Contact details for funding organisations participating in call 2022
Additional information and Q&A regarding the JTC2022 were provided in the Information Event and can be consulted here.
ITALY (IT-MoH): Pre-eligibility check form for IT-MoH proposals (to be sent to IT-MoH at least 10 working days before the JTC submission deadline).
ITALY (FRRB): Pre-eligibility check form for FRRB proposals (to be sent to FRRB at least 10 working days before the JTC submission deadline) and budget tool as support for FRRB applicants.
ITALY (TuscReg): Pre-eligibility check form for TuscReg proposals and budget compilation form for TuscReg proposals (both to be sent to TuscReg at least 10 working days before the JTC submission deadline).
SPAIN (ISCIII and FCAECC): Additional application form for partners requesting funds from ISCIII and FCAECC (to be sent as annex of BOTH pre-proposal and full proposal submission form via the online submission tool).
ISRAEL (CSO-MOH): National additional document (to be sent to CSO-MOH before the JTC submission deadline).
Data Management Plan (DMP) – will be requested ONLY from funded proposals (available now)

AIMS OF THE CALL

With its fifth transnational call (non-cofunded by the EC), ERA PerMed aims to foster research in prevention in personalised medicine. The overarching goal of the call is the development of tailor-made strategies for prevention of disease and disease progression, at three different levels:

i. preventive measures decreasing the rate of incidence (primary prevention),
ii. early detection to increase the efficacy of a preventive therapy, even before symptoms are developed (secondary prevention), and
iii. interventions preventing disease recurrence or improving patients’ care and quality of life (tertiary prevention).

Research on prevention from over-treatment or overmedicalisation in primary, secondary and tertiary personalised preventive approaches is optional and could be part of research proposals, if applicable.

The clinical relevance of the proposed PM approach needs to be convincingly demonstrated.

The overall objectives of the ERA PerMed call are to:

Support translational research projects in the field of personalised medicine;
Encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical or clinical research with bio-informatics components as well as ELSA research or implementation research, including health economics;
Encourage collaboration between academia (research teams from universities, higher education institutions, public research institutions, research centres), clinical/public health research (research teams from hospital/ public health, healthcare settings and other healthcare organisations), private partners e.g. SMEs (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient organisations.

As Personalised Medicine is non-disease-specific, but rather an overall approach that can be adopted and adapted to a multiplicity of medical conditions, research projects in every disease entity are encouraged. The involvement of partners with the respective expertise in the consortium is required.

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

SCOPE OF THE CALL

The JTC2022 is constructed around the following three research areas in order to ensure the development of specific PM approaches considering the major aspects needed for their successful implementation in the health systems: (1) “Translating Basic to Clinical Research and Beyond”, (2) “Data and Information and Communication Technology (ICT)” and (3) “Responsible and Effective Implementation in Healthcare”.

Each proposal MUST address at least one module out of each research area:

Assessment of the coherent integration and combination of the different research areas and modules in the proposals is part of the evaluation process.

GENERAL (eligibility) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

A. Academia (research teams working in universities, other higher education institutions) or research institutes;

B. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;

C. Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual ERA PerMed funding organisation respective of the region/country from which applicants have applied. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “Contact details of participating members”).

Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate to the call (see list below). All three legal entities must be independent from each other. At least two partners out of the minimum three eligible project partners of the consortium must be from two different EU Member States or Associated Countries.

The maximum number of partners per pre-proposal is six though not more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding). At the full-proposal stage, a consortium might be increased up to seven partners in total only by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to coordinators invited for full-proposals submission.

Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates as such. No more than one partner with own funding is allowed in consortia with at least three partners eligible for funding.

The project coordinator must be eligible to be funded by his/her regional/national participating funding organisation.

It is mandatory to integrate as principle investigator at least one early-career researcher in a consortium.

Exception: To facilitate the integration of patient organisations in consortia, they can be added to a consortium as additional partners at the pre-proposal stage or the full-proposal stage. The consortia must follow all of the above-mentioned rules regarding consortia composition without counting the patient organisations. The latter can be added as additional partners either through their own funding or by applying for funding, if eligible, from the respective funding organisations. Not more than two consortium partners per country can request funding, including patient organisations. An exception is possible in countries with more than one funding organisation: in these countries, three partners from the same country may apply for funding, if one of them is a patient organisation and at least one of them is requesting funding to a regional funding organisation.

* minimum 3 partners eligible for funding from three different countries participating in the call. Patient organisations are not counted in this calculation.

** patient organisations are not counted in this calculation and can be added as partners participating with own funding in the pre- and full-proposal step.

*** patient organisations are not counted in this calculation and can be added as additional partners in the pre-proposal or full-proposal stage. They can participate either on own funds or apply for funding, if eligible, from the regional/national funding organisation. Please note: Not more than two consortium partners per country can request funding, including patient organisations. For some funding agencies, the maximum number of eligible partners that can be funded in one project is limited to one. In countries with more than one funding organisation, three partners from the same country may apply for funding, if one of them is a patient organisation and at least one of them is requesting funding to a regional funding organisation.

Peer Review Panel

The list of scientific experts that conformed the Peer Review Panel of the full proposals evaluation can be consulted here.

ICPerMed Partnering tool

If you are looking for potential partners, please have a look also at the ICPerMed Partnering Tool for Personalised Medicine Research. To access it, please follow this link.

The ICPerMed Partnering Tool facilitates networking among universities, clinical sector, research and patient organisations, SMEs, industry and all other stakeholders interested in personalised medicine. The tool enables users to present their expertise to the personalised medicine research community and to search for partners. By completing and activating the profile, it becomes available to all users. The partner search function is available for all users, also for those who do not publish their partnering profile. The tool assists users in finding suitable cooperation partners. The tool might be of particular help for applicants coming from countries that joined ERA PerMed calls recently.

Contact details of participating members

The following countries (26) are participating in the preparation of the call: Austria, Belgium, Brazil, Canada, Chile, Croatia, Denmark, Estonia, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Lithuania*, Luxembourg, Norway, Poland, Romania, Slovenia, South Africa, Spain, Sweden, Taiwan and Turkey (contact list is provided below).

Besides national funders, the following regions are participating (7): Wallonia-Brussels (Belgium), Quebec (Canada), Federation Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain), and one Charity (AECC-FC).

* The decision on participation is still pending for a funding organisation of this country.

The contact list is accessible: here

Contact details of national patients organisations

The following national patients organisations have expressed their interest in participating in previous ERA PerMed calls. For further information and contact details: here.

If there is any other patient organisation interested in participating in the JTC2022, please contact the JCS2022 or join the ICPerMed Partnering Tool.

EP PerMed Information Day

European Partnership for Personalised Medicine calling for national and regional involvement.

The EP PerMed Information Day took place on May May 31, 2021 (13.00 – 16.30 CEST) as an online event.

The initiatives ICPerMed and ERA PerMed invited all interested stakeholders, in particular national and regional authorities (as ministries, funders, etc.) to the virtual event “European Partnership for Personalised Medicine calling for national and regional involvement” to inform about ICPerMed and ERA PerMed’s proposal for EP PerMed, its objectives, activities and expected impacts and the overall framework for engagement in this partnership.

Aim of the information day was to engage with national and regional authorities, funders and stakeholders interested in promoting and implementing personalised medicine approaches in their countries and regions to foster personalised diagnostics, therapy and prevention for the benefit of patients and citizens.

The virtual event took place on May 31, 2021 (13.00 – 16.30 CEST).

Draft Agenda

Presentations:

Presentation Draft Concept Paper EP PerMed

Presentation Guideline Paper EP PerMed

EP PerMed Information Sheets

During the Information Day for EP PerMed that will be held on 31st May 2021, different key aspects and perspectives of the future partnership will be adressed.

In the following EP PerMed Information Sheets further information about these aspects can be found:

Information Sheet 1: Summary of the EP PerMed Draft Concept Paper
Information Sheet 2: Stakeholder Community
Information Sheet 3: National Hubs for PM
Information Sheet 4: Regional Opportunities
Information Sheet 5: Joint Funding Activities
Information Sheet 6: Industry Involvement
Information Sheet 7: International Perspective

Private: Elementor #5632

The European Partnership for Personalised Medicine (EP PerMed) has been proposed in the framework of the EU’s 9th Framework Programme for Research and Innovation, Horizon Europe. Its aim is to align and promote regional and national priority setting and funding for research and implementation projects in the field of personalised medicine among the EU Member States, regions and associated countries as well as international partner countries.

European Partnerships will in Horizon Europe replace previous forms of partnerships, e.g. ERA-Nets or JPIs. Their general aim is to bring the European Commission and private and/or public partners together to address some of Europe’s most pressing challenges through concerted research and innovation initiatives. European partnerships are expected to establish formal and regular collaboration with other relevant research and innovation initiatives and they are a key implementation tool of Horizon Europe, and contribute significantly to achieving the EU’s political priorities.

Over the last years, a great progress has been achieved in the field of personalised medicine by a large number of international, pan-European, national as well as regional activities and initiatives, including ERA PerMed. But to further develop and foster promising personalised medicine approaches, there is a need of an even closer collaboration and effort which could be achieved by such a European Partnership for Personalised Medicine under Horizon Europe.

ERA PerMed promotes the establishment of this European Partnership together with the closely connected International Consortium for Personalised Medicine (ICPerMed).

EP PerMed Information Day: “European Partnership for Personalised Medicine calling for national and regional involvement” will take place on May 31, 2021 (13.00 – 16.30 CEST) in a virtual format. More information is available here.

EP PerMed

EP PerMed: Towards a European Partnership in Personalised Medicine

European Partnerships will in Horizon Europe replace previous forms of partnerships, e.g. ERA-Nets or JPIs. Their general aim is to bring the European Commission and private and/or public partners together to address some of Europe’s most pressing challenges through concerted research and innovation initiatives. Identifying European Partnerships is an integral part of Horizon Europe’s strategic planning process. Under Horizon Europe partnerships are expected to establish formal and regular collaboration with other relevant research and innovation initiatives.

ERA PerMed promotes the establishment of this European Partnership together with the closely connected to ICPerMed.

So far, the following steps that have been done in preparation of this new initiative are:

The next important steps in 2022 in preparation of EP PerMed will be:

Indicative budget request of the Member States for their contribution to the EP PerMed, expected latest for April 2022.
The development of a Personalised Medicine Strategic Research and Innovation Agenda (PM SRIA) in the course of 2022.
The publication of the call for the co-funded European Partnership for Personalised Medicine end of 2022.

The EP PerMed proposal submission will take place in 2023 and the partnership is supposed to be launched by the end of 2023.

JOINT TRANSNATIONAL CALL 2018

“RESEARCH PROJECTS ON PERSONALISED MEDICINE – SMART COMBINATION OF PRE-CLINICAL AND CLINICAL RESEARCH WITH DATA AND ICT SOLUTIONS”

This call is closed

ERA PerMed is a new ERA-Net Cofund, supported by 31 partners of 22 countries and cofunded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in PM, and enhance the European collaboration with non-EU countries, 31 funding organisations have agreed to launch the first Joint Transnational Call for collaborative innovative research projects in Personalised Medicine (PM).

25 successful projects were selected to be co-funded with a total investment of more than 28M€ by this JTC2018. The detailed description of the projects is published in the ERA PerMed 1^thNewsletter.

Contact person for the Joint Call Secretariat (JCS):

The ERA PerMed Joint Call Secretariat is hosted by the National Institute of Health Carlos III:

Mauricio García Franco
Calle Monforte de Lemos 5, 28029 Madrid, SPAIN
Phone: +34 91822 28 85
Email: eranetpm@isciii.es

CALL Documents

Call Text
Guidelines for Applicants

Peer Review Panel

The list of scientific experts that conformed the Peer Review Panel of the full proposals evaluation can be consulted here.

Contact details of participating members

Austria, Belgium, Canada (Quebec), Croatia, Denmark, Estonia, Finland, France, Germany (Saxon), Hungary, Ireland, Israel, Italy (Lombardy), Latvia, Luxembourg, Netherlands, Norway, Poland, Romania, Slovenia, Spain (Catalonia, Navarre), Sweden and Turkey.

Country	Funding Organisation	Contact point	Email
AUSTRIA	FWF	Stephanie Resch Iris Fortmann	Stephanie.Resch@fwf.ac.at Iris.Fortmann@fwf.ac.at
BELGIUM	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
CANADA	CIHR	Adrian Puga	adrian.puga@cihr-irsc.gc.ca
CANADA (QUEBEC)	FRQS	Anne-Cécile Desfaits	Annececile.desfaits@frq.gouv.qc.ca
CROATIA	MSE	Staša Skenžić Alan Hrvoje Pavletić Alen Hutinovic	Stasa.Skenzic@mzo.hr AlanHrvoje.Pavletic@mzo.hr Alen.Hutinovic@mzo.hr
DENMARK	InnoFond	Ejner Moltzen	Ejner.moltzen@innofond.dk
ESTONIA	ETAg	Aare Ignat	Aare.Ignat@etag.ee
ESTONIA	MSA	Angela Ivask	angela.ivask@sm.ee
FINLAND	AKA	Jukka Reivinen	jukka.reivinen@aka.fi nina.kaminen-ahola@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF/DLR	Katja Kuhlmann Wolfgang Ballensiefen	katja.kuhlmann@dlr.de wolfgang.ballensiefen@dlr.de
GERMANY (SACHSEN)	SMWK	Eva Damm Gabriele Süptitz	permed@smwk.sachsen.de
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
IRELAND	HRB	Dr Caitriona Creely	ccreely@hrb.ie
ISRAEL	CSO-MOH	Yahaloma Gat	y.gat@moh.gov.il
ITALY	IT-MoH	Dr. Gaetano Guglielmi Dr. Maria Josè Ruiz Alvarez	g.guglielmi@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Gianni D’Errico Carmen De Francesco	gianni.derrico@frrb.it carmen.defrancesco@frrb.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Mihaela Manole Nicoleta Dumitrache	Mihaela.manole@uefiscdi.ro Nicoleta.dumitrache@uefiscdi.ro
SLOVENIA	MIZS	Dr. Eva Batista	eva.batista@gov.si
SPAIN	ISCIII	Victor Estrada Dori Campo	eranetpm@isciii.es
SPAIN	CDTI	Juan Luis Romera Javier Canizares	juanluis.romera@cdti.es javier.canizares@cdti.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Malin Eklund	Malin.Eklund@vr.se
THE NETHERLANDS	ZonMw	Erica Hackenitz	Hackenitz@zonmw.nl
TURKEY	TUBITAK	Mumine Kucukdemir	mumine.kucukdemir@tubitak.gov.tr

JOINT TRANSNATIONAL CALL 2019

“PERSONALISED MEDICINE: MULTIDISCIPLINARY RESEARCH TOWARDS IMPLEMENTATION”

This call is closed

This is the second ERA PerMed Joint Transnational Call for research projects in PM.

22 successful consortia were selected to be funded with a total investment of more than 24 M€ by this JTC2019. The description of the projects is published in the ERA PerMed 3^thNewsletter.

Contact person for the Joint Call Secretariat (JCS):

The ERA PerMed JCS is hosted by The French National Research Agency (ANR):

Monika Frenzel
50 Avenue Daumesnil, 75012 Paris, FRANCE
Tel: +33 (0) 1 73 54 83 32
Mail: ERAPerMed@agencerecherche.fr

CALL Documents

Peer Review Panel

The list of scientific experts that conformed the Peer Review Panel of the full proposals evaluation can be consulted here.

Contact details of participating members

The further countries (22) are participating in the call: Austria, Belgium, Canada, Croatia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Poland, Romania, Spain, Sweden and Turkey.

The further regions (6) are participating in the call: Quebec (Canada), Saxon (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain).

Country	Funding Organisation	Contact point	Email
AUSTRIA	FWF	Stephanie Resch Iris Fortmann	Stephanie.Resch@fwf.ac.at Iris.Fortmann@fwf.ac.at
BELGIUM	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
CANADA	CIHR	Ilana Gombos	Ilana.Gombos@cihr-irsc.gc.ca
CANADA (QUEBEC)	FRQS	Maxime Beaudoin	Maxime.beaudoin@frq.gouv.qc.ca
DENMARK	InnoFond	Ejner Moltzen Jens Peter Vittrup	Ejner.moltzen@innofond.dk Jens.peter.vittrup@innofond.dk
FINLAND	AKA	Sara Illman	sara.illman@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF/DLR	Katja Kuhlmann Petra Lüers	katja.kuhlmann@dlr.de Petra.Lueers@dlr.de
GERMANY	BMG/VDI/VDE	Dr. Anne Dwertmann Dr. Andrea Repen	Anne.Dwertmann@vdivde-it.de Andrea.Repen@vdivde-it.de
GERMANY (SACHSEN)	SMWK	Eva Damm Gabriele Süptitz	permed@smwk.sachsen.de
GREECE	GSRT	Georgia Kostopoulou	g.kostopoulou@gsrt.gr
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
IRELAND	HRB	Dr Caitriona Creely	ccreely@hrb.ie
ISRAEL	CSO-MOH	Yahaloma Gat	y.gat@moh.gov.il
ITALY	IT-MoH	Dr. Gaetano Guglielmi Dr. Maria Josè Ruiz Alvarez	g.guglielmi@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Carmen De Francesco Paola Larghi Paola Bello	carmen.defrancesco@frrb.it paola.larghi@frrb.it paola.bello@frrb.it
ITALY (TUSCANY)	TUSCREG	Donatella Tanini Teresa Vieri	erapermed@regione.toscana.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Cristina Laura COTET	cristina.cotet@uefiscdi.ro
SPAIN	ISCIII	Mauricio Garcia Franco Eduard Güell Del Frago	mauriciog@isciii.es eguell@externos.isciii.es
SPAIN	CDTI	Sara Alfonso	sara.alfonso@cdti.es
SPAIN	AECC-FC	Marta Puyol	marta.puyol@aecc.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Malin Eklund	Malin.Eklund@vr.se
TURKEY	TUBITAK	Banu Gökcay	banu.buruk@tubitak.gov.tr

JOINT TRANSNATIONAL CALL 2020

“Multidisciplinary Research Projects on Personalised Medicine – Pre-/Clinical research, Big Data and ICT, Implementation and User’s Perspective”

This call is closed

This is the third ERA PerMed Joint Transnational Call for research projects in PM.

18 successful consortia were selected to be funded with a total investment of more than 23M€ by this JTC2020. The detailed description of the projects is published in the ERA PerMed 5^thNewsletter.

Contact person for the Joint Call Secretariat (JCS):

The ERA PerMed JCS2020 is hosted by the German Aerospace Center e.V. – Project Management Agency, (DLR-PT):

Katja Kuhlmann, Alexandra Becker
Heinrich-Konen-Straße 1, 53227 Bonn, GERMANY
Tel +49 (0) 228 3821 2211
Mail permed@dlr.de

CALL Documents

Call Text
Guidelines for Applicants
Data Management Plan (DMP)– will be requested only from funded proposals.

Peer Review Panel

The list of scientific experts that conformed the Peer Review Panel of the full proposals evaluation can be consulted here.

Contact details of participating members

The following countries (23) are participating in the call: Belgium, Canada, Croatia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Panama, Poland, Romania, Slovenia, Spain, Sweden and Turkey.

The following regions (6) are participating in the call: Quebec (Canada), Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain).

The contact list is accessible here.

Private:

JTC2018

ERAPerMed joint call 2021 partners

Country	Region/Organisation	Funding Contact Point	Email
AUSTRIA	F.R.S.-FWF	Milojka Gindl Ena Linnau	milojka.gindl@fwf.ac.at Ena.Linnau@fwf.ac.at
BELGIUM	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
BRAZIL	CONFAP	Elisa Natola	elisa.confap@gmail.com
CHILE	ANID	Andrea Cibotti	acibotti@anid.cl
CROATIA	MSE	Mateo A. Bosnić	MateoAnte.Bosnic@mzo.hr
DENMARK	InnoFond	Ejner Moltzen Jens Peter Vittrup	Ejner.moltzen@innofond.dk Jens.peter.vittrup@innofond.dk
EGYPT	ASRT	Radwan Amro Salma Essawi	Radwan.Amro@gmail.com Sme@sti.sci.eg
ESTONIA	ETAg	Maarja Adojaan Margit Suuroja	Maarja.Adojaan@etag.ee Maarja.Adojaan@etag.ee
FINLAND	AKA	Heikki Vilen	heikki.vilen@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF	Dr. Katja Kuhlmann Lorna Moll	permed@dlr.de
GERMANY	BMG	Dr. Katja Kuhlmann Lorna Moll	permed@dlr.de
GERMANY (SACHSEN)	SMWK	Dr. Eva Maria Stegemann Gabriele Süptitz	permed@smwk.sachsen.de
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
ISRAEL	CSO-MOH	Yahaloma Gat Liron Even-Faitelson	y.gat@moh.gov.il liron.ef@moh.gov.il
ITALY	IT-MoH	Dr. Monica Paganelli Dr. Maria Josè Ruiz Alvarez	m.paganelli@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Carmen De Francesco Paola Bello	bandi@frrb.it
ITALY (TUSCANY)	TuscReg	Donatella Tanini Teresa Vieri	erapermed@regione.toscana.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
PANAMA	SENACYT	Carlos Aguirre	caguirre@senacyt.gob.pa
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Cristina Cotet	cristina.cotet@uefiscdi.ro
SPAIN	ISCIII	Mauricio Garcia-Franco Candi Sánchez Barco Cristina Nieto García	eranetpm@isciii.es
SPAIN	FCAECC	Esther Aguilar Fadó Marta Puyol	esther.aguilar@aecc.es marta.puyol@aecc.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Johan Nilsson	Johan.Nilsson@vr.se
TURKEY	TUBITAK	Emine Derebay Yildiz	emine.derebay@tubitak.gov.tr

JOINT TRANSNATIONAL CALL 2021

“MULTIDISCIPLINARY RESEARCH PROJECTS ON PERSONALISED MEDICINE – DEVELOPMENT OF CLINICAL SUPPORT TOOLS FOR PERSONALISED MEDICINE IMPLEMENTATION”

The call is closed.

ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 30 funding organisations have agreed to launch the fourth Joint Transnational Call for collaborative innovative research projects in PM. This represents the third additional call non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 24 Mio € (approx.).

Opening of online submission tool: 14 December 2020
Submission deadline for pre-proposals: 4 March 2021 (17:00 CET)
Opening of online submission tool for full-proposals: 13 May 2021
Submission deadline for invited full-proposals: 17 June 2021 (17:00 CET)

Electronic submission website

Electronic proposal submission is mandatory on PT-Outline. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on “Sign up” and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The ERA PerMed JCS is hosted by the Italian Ministry of Health (It-MoH):

Viale Ribotta, 5 Roma, ITALY
With the support of the Fondazione Regionale per la Ricerca Biomedica, (FRRB), Lombardy (Italy).
Maria Jose Ruiz Alvarez, Monica Paganelli
Phone: +39 06 5994 3214 / 2408
Email: healthresearch@sanita.it

CALL Documents

The call text and all additional documents can be downloaded below or on the online submission tool:

Call Text (updated 14-04-2021)
Guidelines for Applicants (updated 14-04-2021)
Pre-Proposal form (updated 14-12-2020)
Full-Proposal form (updated 21/05/2021)
Annex template for exploratory clinical studies (updated 29-12-2020)
Contact details for countries participating in call 2021 (updated 14-04-2021)
ITALY (IT-MoH): Pre-eligibility check form for IT-MoH proposals (to be sent to IT-MoH at least 10 working days before the JTC submission deadline).
ITALY (FRRB): Pre-eligibility check form for FRRB proposals (to be sent to FRRB at least 10 working days before the JTC submission deadline) and budget tool as support for FRRB applicants.
ITALY (TuscReg): Pre-eligibility check form for TuscReg proposals and budget compilation form for TuscReg proposals (both to be sent to TuscReg at least 10 working days before the JTC submission deadline).
SPAIN (ISCIII and FCAECC): Additional application form for partners requesting funds from ISCIII and FCAECC (to be sent as annex of BOTH pre-proposal and full proposal submission form via the online submission tool).
Data Management Plan (DMP) – will be requested ONLY from funded proposals

AIMS OF THE CALL

With its fourth transnational call (non-cofunded by the EC), ERA PerMed fosters research and innovation activities that build close linkages between clinical research, computer science/medical informatics and research on ethical, legal and social aspects (ELSA) in the field of PM. This implies a wide range of multidisciplinary activities brought together by different stakeholders from academia, clinical/public health research and private partners such as small and medium-sized enterprises (SMEs), policy makers, regulatory/health technology assessment (HTA) agencies and patients/patient organisations.

The overarching goal is to improve disease prevention and disease management, based on broader and more efficiently characterised and defined patient stratification, diagnostics and tailored treatment/prevention protocols for both patients and individuals at risk of disease. Early involvement of regulatory authorities and close interaction with the different key contributors along the value chain should be included right from the project development phase to bridge the gap between first discoveries or inventions to market access.

Research proposals submitted under this call are expected to demonstrate the applicability of project outcomes to clinical practice and to combine clinical research with data technologies. This could be the development and application of clinical decision support tools by using artificial intelligence (AI) systems approaches, including machine learning technologies. The clinical relevance of the proposed PM approach needs to be convincingly demonstrated. Moreover, proposals must include research on ethical, legal and social aspects.

As Personalised Medicine is non-disease-specific, but rather an overall approach that can be adopted and adapted to a multiplicity of medical conditions, research projects in every disease entity are encouraged.

The involvement of partners with the respective expertise in the consortium is required.

Additionally, projects may include pre-clinical research as a prerequisite for the implementation of a PM approach into clinical practice. Multilevel health economic assessment is also considered to be important for facilitating the translation of PM approaches to healthcare and can be included in the work plan.

The overall objectives of the call are to:

Support translational and transnational research projects in the field of PM;
Encourage and enable interdisciplinary collaborations towards the implementation of PM, combining clinical research with bio-informatics components and research on relevant ethical, legal and social aspects. Additionally, pre-clinical and health economic research can be included if the added value is outlined;
Encourage collaboration between academia (research teams from universities, higher education institutions, public research institutions, research centres), clinical/public health research (research teams from hospital/ public health, healthcare settings and other healthcare organisations), private partnersg. SMEs[1] (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient representative organisations.

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

SCOPE OF THE CALL

Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration.

The JTC2021 is constructed around the following three research areas in order to ensure the development of specific PM approaches, taking into account the major aspects for their successful implementation in the health systems: (1) “Translating Basic to Clinical Research and Beyond”, (2) “Data and Information and Communication Technology (ICT)” and (3) “Research towards Responsible Implementation in Healthcare”:

Each proposal MUST address the modules 1B “Clinical Research”, 2 “Towards Application in Healthcare” and 3B “Ethical, Legal and Social Aspects”. Inclusion of modules 1A “Pre-clinical Research” and 3A “Health Economic Research” is optional. Their added value to the proposal and the mandatory modules has to be clearly described.

GENERAL (eligibility) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to one of the following categories (A, B and/or C), if eligible according to their respective regional/national funding organisation’s regulations for research funding:

Academia (research teams working in universities, other higher education institutions)or research institutes;
Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
(Industry) Private partners, e.g. SMEs^[2](small and medium-size enterprises).

Although proposals will be submitted jointly by research groups from several regions/countries, research groups will be funded by the respective funding organisation of the region/country from which they have applied. Applicants are therefore subject to the eligibility criteria of their respective funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also “Contact details of participating members”).

Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countrieswhose funders participate in the call. All three legal entities must be independent of each other. At least two partners of the minimum three eligible project partners of the consortium must be from two different EU Member States or Associated Countries.

The project coordinator must be eligible to be funded by his/her regional/national participating funding organisations. The maximum number of partners at the pre-proposal stage is six.

Within one consortium, no more than 2 partners from the same country participating in the call will be accepted, including those partners with their own funding).

Partners not eligible for funding by one of the organisations participating in this JTC (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in projects provided that they demonstrate, with the full-proposal submission, that their economic and human resources have already been secured and will be available at the start of the project. No more than one partner with own funding is allowed in consortia with at least 3 partners that are eligible for funding.

At the full-proposal stage, a consortium might be increased to up to seven partners in total by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to all coordinators invited for full-proposals submission.

* minimum 3 partners eligible for funding from three different countries participating to the call

Peer Review Panel

The list of scientific experts that conformed the Peer Review Panel of the full proposals evaluation can be consulted here.

Contact details of participating members

The following countries (23) are already participating in the preparation of the call: Austria, Belgium, Brasil, Chile*, Croatia, Denmark, Finland, France, Egypt, Estonia, Germany, Hungary, Israel, Italy, Latvia, Luxembourg, Norway, Panama, Poland, Romania, Spain, Sweden and, Turkey.

The following regions (5): Saxony (Germany), Lombardy (Italy), Tuscany (Italy) and Catalonia (Spain) and Navarre (Spain); and one Charity (AECC-FC).

The contact list is accessible: here

Contact details of national patients organisations

The following national patients organisations have expressed their interest in participating in the JTC2021. For further information and contact details: here

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

[2] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

If you’d like to receive our Newsletter in your email, please sign in the form below.

First name

Last name

Gender

Organization

Country

By continuing, you accept the privacy policy

[Newsletter]

Estado de la suscripción

Suscripción activada correctamente.

ERAPerMed joint call 2020 partners

Country	Region/Organisation	Funding Contact Point	Email
BELGIUM	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
CANADA (QUEBEC)	FRQS	Maxime Beaudoin	Maxime.beaudoin@frq.gouv.qc.ca
CROATIA	MSE	Mateo A. Bosnić	MateoAnte.Bosnic@mzo.hr
DENMARK	InnoFond	Ejner Moltzen Jens Peter Vittrup	Ejner.moltzen@innofond.dk Jens.peter.vittrup@innofond.dk
EGYPT	ASRT	Radwan Amro Salma Essawi	Radwan.Amro@gmail.com Sme@sti.sci.eg
FINLAND	AKA	Heikki Vilen	heikki.vilen@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF	Dr. Katja Kuhlmann	permed@dlr.de
GERMANY	DLR	Dr. Alexandra Becker	permed@dlr.de
GERMANY	BMG	Dr. Sebastian Delbrück	Sebastian.Delbrueck@vdivde-it.de
GERMANY	VDI/VDE-IT	Dr. Anne Dwertmann	Anne.Dwertmann@vdivde-it.de
GERMANY (SACHSEN)	SMWK	Dr. Eva Maria Stegemann Gabriele Süptitz	permed@smwk.sachsen.de
GREECE	GSRT	Georgia Kostopoulou	g.kostopoulou@gsrt.gr
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
IRELAND	HRB	Dr Louise Drudy	ldrudy@hrb.ie
ISRAEL	CSO-MOH	Yahaloma Gat	y.gat@moh.gov.il
ITALY	IT-MoH	Dr. Monica Paganelli Dr. Maria Josè Ruiz Alvarez	m.paganelli@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Carmen De Francesco Paola Bello	bandi@frrb.it
ITALY (TUSCANY)	TuscReg	Donatella Tanini Teresa Vieri	erapermed@regione.toscana.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
PANAMA	SENACYT	Carlos Aguirre	caguirre@senacyt.gob.pa
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Cristina Cotet	cristina.cotet@uefiscdi.ro
SLOVENIA	MIZS	Eva Batista	Eva.Batista@gov.si
SPAIN	ISCIII	Mauricio Garcia-Franco Candi Sánchez Barco Cristina Nieto García	eranetpm@isciii.es
SPAIN	CDTI	Héctor González	hector.gonzalez@cdti.es
SPAIN	FCAECC	Esther Aguilar Fadó Marta Puyol	esther.aguilar@aecc.es marta.puyol@aecc.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Johan Nilsson	Johan.Nilsson@vr.se
TURKEY	TUBITAK	Emine Derebay Yildiz	emine.derebay@tubitak.gov.tr

ERAPerMed joint call 2019 partners

Country	Region Organisation	Funding Contact Point	Email
AUSTRIA	FWF	Stephanie Resch Iris Fortmann	Stephanie.Resch@fwf.ac.at Iris.Fortmann@fwf.ac.at
BELGIUM	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
CANADA	CIHR	Ilana Gombos	Ilana.Gombos@cihr-irsc.gc.ca
CANADA (QUEBEC)	FRQS	Maxime Beaudoin	Maxime.beaudoin@frq.gouv.qc.ca
CROATIA	MSE	Staša Skenžić	Stasa.Skenzic@mzo.hr
DENMARK	InnoFond	Ejner Moltzen Jens Peter Vittrup	Ejner.moltzen@innofond.dk Jens.peter.vittrup@innofond.dk Radwan.Amro@gmail.com
EGYPT	ASRT	Amr Radwan Salma Essawi	Radwan.Amro@gmail.com Sme@sti.sci.eg, innov@sti.sci.eg
FINLAND	AKA	Heikki Vilen	heikki.vilen@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF	Dr. Katja Kuhlmann	katja.kuhlmann@dlr.de
GERMANY	DLR	Dr. Petra Lüers	Petra.Lueers@dlr.de
GERMANY	BMG/VDI/VDE	Dr. Anne Dwertmann Dr. Andrea Repen	Anne.Dwertmann@vdivde-it.de Andrea.Repen@vdivde-it.de
GERMANY (SAXONY)	SMWK	Eva Damm Gabriele Süptitz	permed@smwk.sachsen.de
GREECE	GSRT	Georgia Kostopoulou	g.kostopoulou@gsrt.gr
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
IRELAND	HRB	Dr Caitriona Creely	ccreely@hrb.ie
ISRAEL	CSO-MOH	Yahaloma Gat	y.gat@moh.gov.il
ITALY	IT-MoH	Dr. Gaetano Guglielmi Dr. Maria Josè Ruiz Alvarez	g.guglielmi@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Carmen De Francesco Paola Larghi Paola Bello	carmen.defrancesco@frrb.it paola.larghi@frrb.it paola.bello@frrb.it
ITALY (TUSCANY)	TUSCREG	Donatella Tanini Teresa Vieri	erapermed@regione.toscana.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Cristina Laura COTET	cristina.cotet@uefiscdi.ro
SPAIN	ISCIII	Mauricio Garcia Franco Eduard Güell	mauriciog@isciii.es eranetpm@isciii.es
SPAIN	CDTI	Sara Alfonso	sara.alfonso@cdti.es
SPAIN	AECC-FC	Marta Puyol	marta.puyol@aecc.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Malin Eklund	Malin.Eklund@vr.se
TURKEY	TUBITAK	Banu Gökcay	banu.buruk@tubitak.gov.tr

ERAPerMed joint call 2018 partners

Country	Region/Organisation	Funding Contact Point	Email
AUSTRIA	FWF	Stephanie Resch Iris Fortmann	Stephanie.Resch@fwf.ac.at Iris.Fortmann@fwf.ac.at
BELGIUM**	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
CANADA	CIHR	Bryan Lemire	bryan.lemire@cihr-irsc.gc.ca
CANADA (QUEBEC)	FRQS	Anne-Cécile Desfaits	Annececile.desfaits@frq.gouv.qc.ca
CROATIA	MSE	Staša Skenžić Alen Hutinovic	Stasa.Skenzic@mzo.hr Alen.Hutinovic@mzo.hr
DENMARK	InnoFond	Ejner Moltzen	Ejner.moltzen@innofond.dk
ESTONIA	ETAg	Aare Ignat	Aare.Ignat@etag.ee
ESTONIA	MSA	Angela Ivask	angela.ivask@sm.ee
FINLAND	AKA	Nina Kaminen-Ahola	nina.kaminen-ahola@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF/DLR	Katja Kuhlmann Wolfgang Ballensiefen	katja.kuhlmann@dlr.de wolfgang.ballensiefen@dlr.de
GERMANY (SACHSEN)	SMWK	Eva Damm Gabriele Süptitz	permed@smwk.sachsen.de
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
IRELAND	HRB	Dr Caitriona Creely	ccreely@hrb.ie
ISRAEL	CSO-MOH	Yahaloma Gat	y.gat@moh.gov.il
ITALY	IT-MoH	Dr. Gaetano Guglielmi Dr. Maria Josè Ruiz Alvarez	g.guglielmi@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Gianni D’Errico Carmen De Francesco	gianni.derrico@frrb.it carmen.defrancesco@frrb.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Mihaela Manole Nicoleta Dumitrache	Mihaela.manole@uefiscdi.ro Nicoleta.dumitrache@uefiscdi.ro
SLOVENIA	MIZS	Dr. Eva Batista	eva.batista@gov.si
SPAIN	ISCIII	Dori Campo	eranetpm@isciii.es
SPAIN	CDTI	Juan Luis Romera Sara Alfonso	juanluis.romera@cdti.es sara.alfonso@cdti.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Malin Eklund	Malin.Eklund@vr.se
THE NETHERLANDS	ZonMw	Erica Hackenitz	Hackenitz@zonmw.nl
TURKEY	TUBITAK	Banu Gokcay	banu.buruk@tubitak.gov.tr

Privacy policy

The ERA PerMed project is coordinated by the National Institute of Health Carlos III.

You may access the document explaining the privacy policy here.

Private: JTC 2020 ANT

“Multidisciplinary Research Projects on Personalised Medicine – Pre-/Clinical research, Big Data and ICT, Implementation and User’s Perspective”

This call is closed

ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 31 funding organisations have agreed to launch the third Joint Transnational Call for research projects in PM. This represents the second of three additional calls non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 27 Mio € (approx.).

Opening of online submission tool: 16 December 2019
Submission deadline for pre-proposals: 5 March 2020 (17:00 CET)
Opening of online submission tool for full-proposals: 18 May 2020
Submission deadline for invited full-proposals: 15 June 2020 (17:00 CEST)

Electronic submission website

Electronic proposal submission is mandatory on PT-Outline. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on “Sign up” and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The ERA PerMed JCS is hosted by the German Aerospace Center e.V. – Project Management Agency, (DLR-PT):

Katja Kuhlmann, Alexandra Becker
Heinrich-Konen-Straße 1, 53227 Bonn, GERMANY
Tel +49 (0) 228 3821 2211
Mail permed@dlr.de

CALL Documents

The call text and all additional documents can be downloaded below or on the online submission tool:

Call Text (updated 23-12-2019)
Guidelines for Applicants (updated 20-02-2020)
Pre-Proposal form (updated 18-12-2019)
ITALY (IT-MoH): Pre-eligibility check form for IT-MoH proposals (to be sent to IT-MoH at least 10 working days before the JTC submission deadline)
ITALY (FRRB): Pre-eligibility check form for FRRB proposals (to be sent to FRRB at least 10 working days before the JTC submission deadline) and budget tool as support for FRRB applicants
ITALY (TuscReg): Pre-eligibility check form for TuscReg proposals and budget compilation form for TuscReg proposals (both to be sent to TuscReg at least 10 working days before the JTC submission deadline)
SPAIN (ISCIII and FCAECC): Additional application form for partners requesting funds from ISCIII and FCAECC (updated 29-05-2020) (to be sent as annex of the FULL proposal submission form via the online submission tool)
Data Management Plan (DMP)– will be requested ONLY from funded proposals

AIMS OF THE CALL

With its third transnational call (non-cofunded by the EC), ERA PerMed fosters research and innovation activities that build close linkages between basic biomedical research, clinical research, physical sciences, bioengineering, bioinformatics and biostatistics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications across the participating countries and beyond. This implies a wide range of multidisciplinary activities brought together by different stakeholders from academia (e.g. universities and research institutions), clinics (e.g. clinical laboratories, medical professionals), industry (e.g. pharmaceutical industry, biotechnology companies, information technology companies including health information technology – HIT), policy makers, regulatory/health technology assessment (HTA) agencies and patients/patient organisations.

The overarching goal is to improve disease prevention and disease management, based on broader and more efficiently characterised and defined patient stratification, diagnostics and tailored treatment protocols. Early involvement of regulatory authorities and close interaction with the different key players along the value chain should be included right from the project development phase to bridge the gap between first discoveries or inventions until market access. Proposals submitted under this call are expected to demonstrate the applicability of project outcomes to clinical practice. The clinical relevance of the proposed PM approach needs to be convincingly demonstrated. Moreover, proposals are expected to include research on ethical, legal and socio-economic implications, including health economics and regulation, and/or research on the optimisation of health care systems. They may also consider patient and citizen empowerment and training strategies for the different stakeholders in PM.

The overall objectives of the call are to:

Support translational research projects in the field of Personalised Medicine;
Encourage and enable interdisciplinary collaborations towards the implementation of PM, combining pre-clinical and/or clinical research with bioinformatics components and research on relevant ethical, legal and social aspects and/or research on the optimisation of health care systems;
Encourage collaboration between academia (research teams from universities, higher education institutions, public research institutions), clinical/public health research (research teams from hospital/ public health, health care settings and other health care organisations), private partners e.g. SMEs^[1] (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient organisations.

Scope OF THE CALL

Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration.

The JTC2020 of ERA PerMed will comprise three Research Areas:

Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals will be part of the evaluation process.

GENERAL (eligibility) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to one of the following categories (A, B and/or C), if eligible according to their respective regional/national funding organisation’s regulations for research funding:

Academia (research teams working in universities, other higher education institutions) or research institutes;
Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
(Industry) Private partners, e.g. SMEs^[2] (small and medium-size enterprises).

Although proposals will be submitted jointly by research groups from several regions/countries, research groups will be funded by the respective funding organisation of the region/country from which they have applied. Applicants are therefore subject to the eligibility criteria of their respective funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also “Contact details of participating members”).

Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funders participate in the call (see list below). All three legal entities must be independent of each other. At least two partners of the consortium must be from two different EU Member States or Associated Countries.

The coordinator must be eligible to be funded by one of the participating funding organisations to this call. The maximum number of partners per pre-proposal is six. No more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding).

Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates as such. No more than one partner with own funding is allowed in consortia with at least 3 partners that are eligible for funding.

At the full-proposal stage, a consortium might be increased to up to seven partners in total by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to all coordinators invited for full-proposals submission.

* minimum 3 partners eligible for funding from three different countries participating to the call

ICPerMed Partnering tool

If you are looking for potential partners, please have a look also at the ICPerMed Partnering Tool for Personalised Medicine Research. To access it, please follow this link.

Contact details of participating members

The following countries (23) are participating in the call: Belgium, Canada, Croatia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Panama, Poland, Romania, Slovenia, Spain, Sweden and Turkey.

The following regions (6) are participating in the call: Quebec (Canada), Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain).

The contact list is accessible here.

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

[2] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

prueba intranet

Mapa Partners

ORGANIZACION PARTICIPANTE	PAIS / REGION	CONTACTO
Fondo de Ciencia Austriaco (FWF)	AUSTRIA	Stephanie Resch Tel: (+43) (0) 1 505 67 40-8201 Iris Fortmann Tel: (+43) (0) 1 505 67 40-8211
Institutos Canadienses de Investigación en Salud, (CIHR)	CANADÁ	Adrián Puga Tel: +1 613-952-5728 adrian.puga@cihr-irsc.gc.ca
Fonds de recherche du Québec – Santé, (FRQS)	CANADA, QUEBEC	Sylvain Charbonneau Tel: 514-873-2114 sylvain.charbonneau@frq.gouv.qc.ca
Ministry of Science and Education of the Republic of Croatia, (MSE)	CROATIA	Staša Skenžić Stasa.Skenzic@mzo.hr Alan Hrvoje Pavletić AlanHrvoje.Pavletic@mzo.hr
Innovation Fund Denmark, (InnoFond)	DENMARK	Ejner Moltzen Tel: (+45) 31330306 Ejner.moltzen@innofond.dk
Estonian Research Council, (ETAg)	ESTONIA	Aare Ignat Tel: +372 73 1 73 64 Aare.Ignat@etag.ee
Estonian Ministry of Social Affairs, (MSA)	ESTONIA	Angela Ivask Tel: +3726269735 angela.ivask@sm.ee
Academy of Finland, (AKA)	FINLAND	Jukka Reivinen Tel: (+358) 029 533 5099 jukka.reivinen@aka.fi
Agence Nationale de la Recherche, (ANR)	FRANCE	Monika Frenzel Tel: (+33) (0) 1 73 54 83 32 ERAPerMed@agencerecherche.fr
Federal Ministry of Education and Research, (BMBF) German Aerospace Centre e.V. – Programme Management Agency, (DLR)	GERMANY	Katja Kuhlmann Tel: +49 228 3821 2211 katja.kuhlmann@dlr.de Wolfgang Ballensiefen wolfgang.ballensiefen@dlr.de
Saxon State Ministry for Higher Education, Research and the Arts, (SMWK)	GERMANY (SACHSEN)	Eva Damm Tel: (+49) 351 564 6425 permed@smwk.sachsen.de Gabriele Süptitz Tel: (+49) 351 564 6422 permed@smwk.sachsen.de
National Research, Development and Innovation Office, (NKFIH)	HUNGARY	Dr. Klára Horváth National Research, Development and Innovation Office Budapest 1077, Kéthly Anna tér 1. +36 1 896 37 48 klara.horvath@nkfih.gov.hu
Health Research Board, (HRB)	IRELAND	Dr Caitriona Creely Tel: (+353) 1234 5204 ccreely@hrb.ie
Chief Scientist Office, Ministry Of Health, (CSO-MOH)	ISRAEL	Yahaloma Gat Tel: (+972) (0) 56 242 476 y.gat@moh.gov.il
Italian Ministry of Health, (IT-MoH)	ITALY	Dr. Gaetano Guglielmi Directorate General for Health Research and Innovation Tel: (+39) 065994.3528 g.guglielmi@sanita.it Dr. Maria Josè Ruiz Alvarez Tel: (+39) 065994.3214 mj.ruizalvarez-esterno@sanita.it
Regional Foundation for Biomedical Research, (FRRB)	ITALY (LOMBARDY)	Paola Larghi Tel: +39 02 6765 0173 paola.larghi@frrb.it Carmen De Francesco Tel: +39 02 6765 0170 carmen.defrancesco@frrb.it
State Education Development Agency (VIAA)	LATVIA	Maija Bundule Tel: +371- 67785423 Maija.Bundule@viaa.gov.lv Uldis Berkis Tel: +371 29472349 Uldis.Berkis@viaa.gov.lv
National Research Fund, (FNR)	LUXEMBOURG	Marie-Claude Marx Tel: +352 261925 – 21 marie-claude.marx@fnr.lu
The Research Council of Norway, (RCN)	NORWAY	Karianne Solaas Tel: (+47) 945 35 380 kso@rcn.no
National Centre for Research and Development, (NCBR)	POLAND	Marcin Chmielewski Tel: +48 22 39 07 109 marcin.chmielewski@ncbr.gov.pl
Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI)	ROMANIA	Mihaela Manole Tel: +40 21 302 38 63 Mihaela.manole@uefiscdi.ro Nicoleta Dumitrache Tel: +40 21 302 38 86 Nicoleta.dumitrache@uefiscdi.ro
Ministry of Education, Science and Sport, (MIZS)	SLOVENIA	Dr. Eva Batista Tel: +38614784754 eva.batista@gov.si
National Institute of Health Carlos III (ISCIII)	SPAIN	Mauricio García-Franco Eduard Güell Tel: +34 9182 22461 mauriciog@isciii.es eranetpm@isciii.es
Centro Tecnológico Industrial, (CDTI)	SPAIN	Juan Luis Romera Tel: +34 5815500 juanluis.romera@cdti.esSara Alfonsosara.alfonso@cdti.esJulián Díaz Tel: +345815500 julian.diaz@cdti.es
Health Department – Generalitat de Catalunya, (DS-CAT)	SPAIN (CATALONIA)	Montserrat Llavayol Tel: +34935566172 peris@gencat.cat
Government of Navarre, (GN)	SPAIN (NAVARRE)	Sara Torres storresl@navarra.es
Swedish Research Council, (SRC)	SWEDEN	Malin Eklund Tel: +46 (0) 76 526 72 56 Malin.Eklund@vr.se
La Organización de los Países Bajos para la Investigación y el Desarrollo de la Salud, (ZonMw)	LOS PAÍSES BAJOS	Erica Hackenitz Tel: + 31-70-3495159 Hackenitz@zonmw.nl
El Consejo de Investigación Científica y Tecnológica de Turquía, (TUBITAK)	PAVO	Mumine Kucukdemir Tel: +90 312 298 1209 mumine.kucukdemir@tubitak.gov.tr

Protected: Access for members

Private: JOINT TRANSNATIONAL CALL 2018 ant

“RESEARCH PROJECTS ON PERSONALISED MEDICINE – SMART COMBINATION OF PRE-CLINICAL AND CLINICAL RESEARCH WITH DATA AND ICT SOLUTIONS”

This call is closed

ERA PerMed is a new ERA-Net Cofund, supported by 31 partners of 22 countries and cofunded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in PM, and enhance the European collaboration with non-EU countries, 31 funding organisations have agreed to launch the first Joint Transnational Call for collaborative innovative research projects in Personalised Medicine (PM). The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.

Opening of online submission tool: 14^th February 2018
Submission deadline for pre-proposals: 10^th April 2018 (17:00 CET)
Submission deadline for full-proposals: 26^th July 2018 (17:00 CET)

Electronic submission website

Research project consortia who intend to submit a transnational proposal should register as soon as possible under https://secure.pt-dlr.de/ptoutline/app/erapermed2018, by clicking on “sign up” and follow further instructions. Electronic proposal submission is mandatory on: https://secure.pt-dlr.de/ptoutline/app/erapermed2018.

Contact person for the Joint Call Secretariat:

The ERA PerMed Joint Call Secretariat is hosted by the National Institute of Health Carlos III:

Dori Campo/Mauricio García/Eduard Güell,

Calle Monforte de Lemos 5, 28029 Madrid, SPAIN

Phone: +34 91822 28 85

Email: eranetpm@isciii.es

CALL Documents

Call Text (updated 06-06-2018)
Guidelines for Applicants (updated 06-06-2018)
Full proposal Submission Form (NOW AVAILABLE)
- Data Management Plan (DMP) – will be requested ONLY from funded proposals
- Exploratory Clinical Studies – to be included in the full proposal if appropriate

Private: JOINT TRANSNATIONAL CALL 2019 ant

“PERSONALISED MEDICINE: MULTIDISCIPLINARY RESEARCH TOWARDS IMPLEMENTATION”

This call is closed

ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 29 funding organisations have agreed to launch the second Joint Transnational Call for collaborative innovative research projects in Personalised Medicine (PM). This represents the first of three potential additional calls not co-funded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.

The call is planned to be launched in January 2019 with a submission deadline for pre-proposals in March 2019. It is expected, that consortia invited for the full-proposal stage, will need to submit their proposal on June 17^th, 2019.

The available budget for this call is 30 Mio€ (approx.).

Document

AIMS OF THE CALL

With its second transnational call, ERA PerMed will foster research and innovation activities building close linkages between basic biomedical research, clinical research, bioinformatics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications.

The overarching goal is to improve disease management, with better patient stratification, diagnostics and treatment protocols, and disease prevention. Proposals submitted under this call are expected to demonstrate the applicability of project outcomes into clinical practice as well as to describe the impact on the health care systems. Proposals are expected to include research on ethical, legal and socio-economic implications, including health economics and regulation, and/or research on optimisation of health care systems.

The overall objectives of the ERA PerMed call are (i) to support translational research projects in the field of Personalised Medicine; (ii) to encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical and/or clinical research with computational components and research on relevant ethical, legal and social aspects (ELSA) and/or research on the optimisation of the health care systems; (iii) to encourage collaboration between academia (research teams from universities, higher education institutions, public research performing institutions), clinical/public health research (research teams from hospital/ public health institutions, healthcare settings and other healthcare organisations) and private partners e.g. SMEs [1] (Small and Medium-size Enterprises).

SCOPE OF THE CALL

Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration.

The JTC2019 of ERA PerMed will comprise three Research Areas:

Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals will be part of the evaluation process.

GENERAL (eligibility) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to one the following categories (A, B and/or C), if eligible according to relevant regional/national funding organisations regulations for research funding:

Academia (research teams working in universities, other higher education institutions) or research institutes;
Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
(Industry) Private partners, e.g. SMEs [2] (small and medium-size enterprises).

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual ERA PerMed funding organisation respective of the region/country from which applicants have applied. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “Contact details of participating members”).

Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate to the call (see list below). All three legal entities must be independent from each other. The maximum number of partners per pre-proposal is six though not more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding).

Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates as such. Maximum one partner with own funding is allowed in consortia with at least 3 partners that are eligible for funding. The coordinator must be eligible to be funded by the participating funding organisations to this call.

At the full-proposal stage, a consortium might be increased up to seven partners in total only by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to coordinators invited for full-proposals submission.

Number of partners in the proposal*	Pre-proposal				Full-proposal (only by inclusion of one underrepresented country)
Number of partners in the proposal*	3	4	5	6	7
Maximum number of partners with own funding	0	1	1	1	1
Maximum number of partners per country	1	2	2	2	2

* minimum 3 partners eligible for funding from three different countries participating to the call

ICPerMed Partnering tool

If you are looking for potential partners, please have a look also at the ICPerMed Partnering Tool: https://partnering.pt-dlr.de/ICPerMed

PARTICIPATING MEMBERS, ASSOCIATED COUNTRIES AND REGIONS

Austria, Belgium, Canada (Quebec), Denmark, Finland, France, Germany (Saxon), Greece, Hungary, Ireland, Israel, Italy (Lombardy, Tuscany), Latvia, Luxembourg, Norway, Poland, Romania, Spain (Catalonia, Navarre), Sweden and Turkey (contact list is provided in Annex 1).

Please Note:

The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication.

Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.

Final call information is expected to be published on the ERA PerMed website by January 2019.

Annex 1: CONTACT DETAILS OF PARTICIPATING MEMBERS

Country	Funding Organisation	Contact point	Email
AUSTRIA	FWF	Stephanie Resch Iris Fortmann	Stephanie.Resch@fwf.ac.at Iris.Fortmann@fwf.ac.at
BELGIUM	F.R.S.-FNRS	Joël Groeneveld Florence Quist	joel.groeneveld@frs-fnrs.be florence.quist@frs-fnrs.be
CANADA	CIHR	Ilana Gombos	Ilana.Gombos@cihr-irsc.gc.ca
CANADA (QUEBEC)	FRQS	Maxime Beaudoin	Maxime.beaudoin@frq.gouv.qc.ca
DENMARK	InnoFond	Ejner Moltzen Jens Peter Vittrup	Ejner.moltzen@innofond.dk Jens.peter.vittrup@innofond.dk
FINLAND	AKA	Sara Illman	sara.illman@aka.fi
FRANCE	ANR	Monika Frenzel	ERAPerMed@agencerecherche.fr
GERMANY	BMBF/DLR	Katja Kuhlmann Petra Lüers	katja.kuhlmann@dlr.de Petra.Lueers@dlr.de
GERMANY	BMG/VDI/VDE	Dr. Anne Dwertmann Dr. Andrea Repen	Anne.Dwertmann@vdivde-it.de Andrea.Repen@vdivde-it.de
GERMANY (SACHSEN)	SMWK	Eva Damm Gabriele Süptitz	permed@smwk.sachsen.de
GREECE	GSRT	Georgia Kostopoulou	g.kostopoulou@gsrt.gr
HUNGARY	NKFIH	Dr. Klára Horváth	klara.horvath@nkfih.gov.hu
IRELAND	HRB	Dr Caitriona Creely	ccreely@hrb.ie
ISRAEL	CSO-MOH	Yahaloma Gat	y.gat@moh.gov.il
ITALY	IT-MoH	Dr. Gaetano Guglielmi Dr. Maria Josè Ruiz Alvarez	g.guglielmi@sanita.it mj.ruizalvarez-esterno@sanita.it
ITALY (LOMBARDY)	FRRB	Carmen De Francesco Paola Larghi Paola Bello	carmen.defrancesco@frrb.it paola.larghi@frrb.it paola.bello@frrb.it
ITALY (TUSCANY)	TUSCREG	Donatella Tanini Teresa Vieri	erapermed@regione.toscana.it
LATVIA	VIAA	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI	Cristina Laura COTET	cristina.cotet@uefiscdi.ro
SPAIN	ISCIII	Mauricio Garcia Franco Eduard Güell Del Frago	mauriciog@isciii.es eguell@externos.isciii.es
SPAIN	CDTI	Sara Alfonso	sara.alfonso@cdti.es
SPAIN	AECC-FC	Marta Puyol	marta.puyol@aecc.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	SRC	Malin Eklund	Malin.Eklund@vr.se
TURKEY	TUBITAK	Banu Gökcay	banu.buruk@tubitak.gov.tr

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

[2] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

PARTNERS

ERA PerMed consortium partners (NSC)

PARTICIPANT ORGANIZATION	COUNTRY/ REGION	CONTACT
Austrian Science Fund, (FWF)	AUSTRIA	Milojka Gindl Tel: +43 1 505 67 40 8209 milojka.gindl@fwf.ac.at Ena Linnau Tel: (+43) (0) 1 505 67 40-8205 Ena.Linnau@fwf.ac.at
Fund for Scientific Research, (FNRS)	BELGIUM	Joël Groeneveld Tel: (+32)2 504 9270 joel.groeneveld@frs-fnrs.be Florence Quist Tel: (+32)2 504 9351 florence.quist@frs-fnrs.be
Canadian Institutes of Health Research, (CIHR)	CANADÁ	Adrián Puga Tel: +1 613-952-5728 adrian.puga@cihr-irsc.gc.ca
Fonds de recherche du Québec – Santé, (FRQS)	CANADA (QUEBEC)	Sylvain Charbonneau Tel: 514-873-2114 sylvain.charbonneau@frq.gouv.qc.ca
Ministry of Science and Education of the Republic of Croatia, (MSE)	CROATIA	Staša Skenžić Stasa.Skenzic@mzo.hr Alan Hrvoje Pavletić AlanHrvoje.Pavletic@mzo.hr
Innovation Fund Denmark, (InnoFond)	DENMARK	Ejner Moltzen Tel: (+45) 31330306 Ejner.moltzen@innofond.dk
Estonian Research Council, (ETAg)	ESTONIA	Aare Ignat Tel: +372 73 1 73 64 Aare.Ignat@etag.ee
Estonian Ministry of Social Affairs, (MSA)	ESTONIA	Mari Teesalu Tel: +372 626 9735 mari.teesalu@sm.ee
Academy of Finland, (AKA)	FINLAND	Heikki Vilen, PhD Tel: (+358) 29 533 5135 heikki.vilen@aka.fi
Agence Nationale de la Recherche, (ANR)	FRANCE	Monika Frenzel Tel: (+33) (0) 1 73 54 83 32 ERAPerMed@agencerecherche.fr
Federal Ministry of Education and Research, (BMBF) German Aerospace Centre e.V. – Programme Management Agency, (DLR)	GERMANY	Katja Kuhlmann Tel: +49 228 3821 2211 katja.kuhlmann@dlr.de Lorna Moll Lorna.Moll@dlr.de
Federal Ministry of Health, (BMG)	GERMANY	Dr. Joachim Burbiel Tel. +49 228 3821-1351 joachim.burbiel@dlr.de Dr. Sophia Schade Sophia.Schade@bmg.bund.de
Saxon State Ministry for Higher Education, Research and the Arts, (SMWK)	GERMANY (SACHSEN)	Eva Damm Tel: (+49) 351 564 6425 permed@smwk.sachsen.de Gabriele Süptitz Tel: (+49) 351 564 6422 permed@smwk.sachsen.de
National Research, Development and Innovation Office, (NKFIH)	HUNGARY	Dr. Klára Horváth Tel: +36 1 896 37 48 klara.horvath@nkfih.gov.hu
Health Research Board, (HRB)	IRELAND	Dr Caitriona Creely Tel: (+353) 1234 5204 ccreely@hrb.ie
Chief Scientist Office, Ministry Of Health, (CSO-MOH)	ISRAEL	Yahaloma Gat Tel: (+972) (0) 56 242 476 y.gat@moh.gov.il
Italian Ministry of Health, (IT-MoH)	ITALY	Dr. Gaetano Guglielmi Tel: (+39) 065994.3528 g.guglielmi@sanita.it Dr. Maria Josè Ruiz Alvarez Tel: (+39) 065994.3214 mj.ruizalvarez-esterno@sanita.it
Regional Foundation for Biomedical Research, (FRRB)	ITALY (LOMBARDY)	Paola Larghi Tel: +39 02 6765 0173 paola.larghi@frrb.it Carmen De Francesco Tel: +39 02 6765 0170 carmen.defrancesco@frrb.it
State Education Development Agency (VIAA)	LATVIA	Maija Bundule Tel: +371- 67785423 Maija.Bundule@viaa.gov.lv Uldis Berkis Tel: +371 29472349 Uldis.Berkis@viaa.gov.lv
National Research Fund, (FNR)	LUXEMBOURG	Marie-Claude Marx Tel: +352 261925 – 21 marie-claude.marx@fnr.lu
The Research Council of Norway, (RCN)	NORWAY	Karianne Solaas Tel: (+47) 945 35 380 kso@rcn.no
National Centre for Research and Development, (NCBR)	POLAND	Marcin Chmielewski Tel: +48 22 39 07 109 marcin.chmielewski@ncbr.gov.pl
Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI)	ROMANIA	Mihaela Manole Tel: +40 21 302 38 63 Mihaela.manole@uefiscdi.ro Nicoleta Dumitrache Tel: +40 21 302 38 86 Nicoleta.dumitrache@uefiscdi.ro
Ministry of Education, Science and Sport, (MIZS)	SLOVENIA	Dr. Eva Batista Tel: +38614784754 eva.batista@gov.si
National Institute of Health Carlos III (ISCIII)	SPAIN	Dr. Cristina Nieto Tel: +34 91 822 2443 eranetpm@isciii.es Dr. Mauricio García-Franco Tel: +34 91 822 2461 Candi Sánchez Barco Tel: +34 91 822 20 63 cbarco@isciii.es
Centro Tecnológico Industrial, (CDTI)	SPAIN	Héctor González Menéndez Tel: +34 91 581 04 89 hector.gonzalez@cdti.es
Health Department – Generalitat de Catalunya, (DS-CAT)	SPAIN (CATALONIA)	Montserrat Llavayol Tel: +34935566172 peris@gencat.cat
Government of Navarre, (GN)	SPAIN (NAVARRE)	Sara Torres storresl@navarra.es
Swedish Research Council, (SRC)	SWEDEN	Malin Eklund Tel: +46 (0) 76 526 72 56 Malin.Eklund@vr.se
The Netherlands Organisation for Health Research and Development, (ZonMw)	THE NETHERLANDS	Rob Diemel Diemel@zonmw.nl
The Scientific and Technological Research Council of Turkey, (TUBITAK)	TURKEY	Mumine Kucukdemir Tel: +90 312 298 1209 mumine.kucukdemir@tubitak.gov.tr

ERA PerMed joint call funding partners
Call Steering Committees, CSCs

CONTACT

Mauricio García Franco Eduard Güell
e-mail:	eranetpm@isciii.es
Telephone :
Address:

FUNDED PROJECTS

ERA PerMed funded projects of the Joint Translational Call 2022 have been published in the ERA PerMed 9th NewsLetter January 2023.

ERA PerMed funded projects of the Joint Translational Call 2021 have been published in the ERA PerMed 7th NewsLetter January 2022.

ERA PerMed funded projects of the Joint Translational Call 2020 have been published in the ERA PerMed 5th NewsLetter January 2021

The Funded projects of the Joint Translational Call 2019 are already included in the ERA PerMed 3rd NewsLetter January 2020

ERA PerMed Results of the Cofunded Joint Translational Call 2018 are available at ERA PerMed 1st NewsLetter January 2019

JOINT CALLS

The ERA PerMed consortium has agreed to yearly launch Joint Transnational Calls covering different topics concerning personalised medicine.

Calls are to be funded by the particular regional/national funding organisations. Please read carefully all documents of the call. The Joint Transnational Call 2022 is open. The pre-proposal submission deadline is on 17 February 2022 (17:00 CET). Please see the Joint Transnational Call 2022 announcement for more details.

Inicio

Previous image

Next image

ERA PerMed is a new ERA-Net Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in PM, and enhance the European collaboration with non-EU countries, national funding organisations have agreed to launch Joint Transnational Calls for collaborative innovative research projects in Personalised Medicine (PM).

Report on SRIA consultation for EP PerMed

EP PerMed: Open Consultation for the SRIA

Publication of the Strategic Research and Innovation Agenda for Personalised Medicine

EP PerMed SRIA

EP PerMed: Open Consultation for the SRIA

European Partnership for Personalised Medicine (EP PerMed)

Strategic Research and Innovation Agenda (SRIA) to support the EP PerMed

Elementor #6779

Draft Proposal “European Partnership on Personalised Medicine”

JOINT TRANSNATIONAL CALL 2022

“PREVENTION IN PERSONALISED MEDICINE”

THE CALL IS CLOSED

Opening of online submission tool: 1st December 2021

Submission deadline for pre-proposals: 17 February 2022 (17:00 CEST)

Submission deadline for invited full-proposals: 14 June 2022 (17:00 CEST)

Electronic submission website

Electronic proposal submission is mandatory on PT-Outline. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on “Sign up” and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The ERA PerMed JCS is hosted by the Agence Nationale de la Recherche (ANR), France:

Monika Frenzel and Michael Joulie

50 Avenue Daumesnil, 75012 Paris, FRANCE

Phone: +33 1 73 54 83 32 / +33 1 80 48 83 57

Email: ERAPerMed@agencerecherche.fr

with the support of the National Health Institute Carlos III (ISCIII), Spain.

CALL Documents

The call text and all additional documents can be downloaded below or on the online submission tool:

Call Text (updated on 16.02.2022)

Guidelines for Applicants (updated on 28.04.2022)

Full-Proposal form (available now)

Annex template for exploratory clinical studies (available now)

Contact details for funding organisations participating in call 2022

Additional information and Q&A regarding the JTC2022 were provided in the Information Event and can be consulted here.

ITALY (IT-MoH): Pre-eligibility check form for IT-MoH proposals (to be sent to IT-MoH at least 10 working days before the JTC submission deadline).

ITALY (FRRB): Pre-eligibility check form for FRRB proposals (to be sent to FRRB at least 10 working days before the JTC submission deadline) and budget tool as support for FRRB applicants.

ITALY (TuscReg): Pre-eligibility check form for TuscReg proposals and budget compilation form for TuscReg proposals (both to be sent to TuscReg at least 10 working days before the JTC submission deadline).

SPAIN (ISCIII and FCAECC): Additional application form for partners requesting funds from ISCIII and FCAECC (to be sent as annex of BOTH pre-proposal and full proposal submission form via the online submission tool).

ISRAEL (CSO-MOH): National additional document (to be sent to CSO-MOH before the JTC submission deadline).

Data Management Plan (DMP) – will be requested ONLY from funded proposals (available now)

AIMS OF THE CALL

With its fifth transnational call (non-cofunded by the EC), ERA PerMed aims to foster research in prevention in personalised medicine. The overarching goal of the call is the development of tailor-made strategies for prevention of disease and disease progression, at three different levels:

Research on prevention from over-treatment or overmedicalisation in primary, secondary and tertiary personalised preventive approaches is optional and could be part of research proposals, if applicable.

The clinical relevance of the proposed PM approach needs to be convincingly demonstrated.

The overall objectives of the ERA PerMed call are to:

Support translational research projects in the field of personalised medicine;

Encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical or clinical research with bio-informatics components as well as ELSA research or implementation research, including health economics;

SCOPE OF THE CALL

Each proposal MUST address at least one module out of each research area:

Assessment of the coherent integration and combination of the different research areas and modules in the proposals is part of the evaluation process.

GENERAL (eligibility) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

A. Academia (research teams working in universities, other higher education institutions) or research institutes;

B. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;

C. Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.

The project coordinator must be eligible to be funded by his/her regional/national participating funding organisation.

It is mandatory to integrate as principle investigator at least one early-career researcher in a consortium.

Peer Review Panel

ICPerMed Partnering tool

If you are looking for potential partners, please have a look also at the ICPerMed Partnering Tool for Personalised Medicine Research. To access it, please follow this link.

Contact details of participating members

Besides national funders, the following regions are participating (7): Wallonia-Brussels (Belgium), Quebec (Canada), Federation Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain), and one Charity (AECC-FC).

* The decision on participation is still pending for a funding organisation of this country.

The contact list is accessible: here

Contact details of national patients organisations

The following national patients organisations have expressed their interest in participating in previous ERA PerMed calls. For further information and contact details: here.

If there is any other patient organisation interested in participating in the JTC2022, please contact the JCS2022 or join the ICPerMed Partnering Tool.

EP PerMed Information Day

EP PerMed Information Sheets

Private: Elementor #5632

EP PerMed

EP PerMed: Towards a European Partnership in Personalised Medicine

JOINT TRANSNATIONAL CALL 2018

“RESEARCH PROJECTS ON PERSONALISED MEDICINE – SMART COMBINATION OF PRE-CLINICAL AND CLINICAL RESEARCH WITH DATA AND ICT SOLUTIONS”

This call is closed

25 successful projects were selected to be co-funded with a total investment of more than 28M€ by this JTC2018. The detailed description of the projects is published in the ERA PerMed 1th Newsletter.

Contact person for the Joint Call Secretariat (JCS):

The ERA PerMed Joint Call Secretariat is hosted by the National Institute of Health Carlos III:

Mauricio García Franco

Calle Monforte de Lemos 5, 28029 Madrid, SPAIN

Phone: +34 91822 28 85

Email: eranetpm@isciii.es

25 successful projects were selected to be co-funded with a total investment of more than 28M€ by this JTC2018. The detailed description of the projects is published in the ERA PerMed 1^thNewsletter.

22 successful consortia were selected to be funded with a total investment of more than 24 M€ by this JTC2019. The description of the projects is published in the ERA PerMed 3^thNewsletter.

18 successful consortia were selected to be funded with a total investment of more than 23M€ by this JTC2020. The detailed description of the projects is published in the ERA PerMed 5^thNewsletter.